Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Specialty Medicine

- PMLiVE

EMA grants AZ’s Vaxzevria COVID-19 vaccine full marketing authorisation

Vaxzevria has been shown to be effective against all forms of COVID-19

- PMLiVE

Act-Accelerator outlines plans for longterm COVID-19 control

Its plan highlights key priorities as countries transition to manage the public health issue

- PMLiVE

NHS England hits ten million in autumn COVID-19 booster campaign

Health leaders have warned of a COVID-19 and flu ‘twindemic’ this winter

- PMLiVE

WHO reveals tuberculosis deaths rose due to COVID-19 disruption

An estimated 10.6 million were infected with TB in 2021, an increase of 4.5% from 2020

Expanding Opportunities for Healthcare with “Digital Twins”

Brad Womble, Senior Director of Strategy, Marketing and Mergers & Acquisitions, at Jabil Healthcare dives into several thought-provoking topics, including how insights from “digital twins” can be used to improve...

Impetus Digital

- PMLiVE

Sight-saving MedTech sleep mask could save the NHS multimillions

MedTech company PolyPhotonix has had its innovative diabetes sleep mask adopted in the NHS for the first time

Onyx Health

Create Health's latest recruits gathered in the agency's Bristol studio

Healthcare marketing agency Create Health continues to grow

Eight new recruits, including Business Development Director, Marketing Manager and Medical Writer join Create Health.

Create Health

- PMLiVE

BMS confirms COVID-19 vaccine immune response in Zeposia-treated MS patients

Over 92% of patients in the analyses mounted a serological response following vaccination

Mindset Matters

Create Health

Closing the Gaps in Telehealth

Anthony Capone, President of DocGo, shares how his company uses last-mile mobile health services and integrated medical transportation solutions to make healthcare more accessible for everyone, including underserved populations.

Impetus Digital

- PMLiVE

Novavax’s COVID-19 vaccine candidate approved for emergency use by FDA as a booster

The authorisation is for those unable to receive an FDA-authorised mRNA bivalent booster

- PMLiVE

Moderna’s Omicron BA.1 booster shows superior antibody response over Spikevax

Data indicates that the superior response is sustained for at least three months

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links